Notably, preclinical models demonstrate that OVs can induce tumor cells to re-express MHC-I and enhance dendritic cell cross-presentation by carrying immunomodulatory genes such as GM-CSF or interferon-gamma (IFN-γ), exemplified by T-VEC’s GM-CSF engineering. The gene discussed is IFNG; the disease is neoplasm.